N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-3-(pyridin-2-yldisulfanyl)propanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-3-(pyridin-2-yldisulfanyl)propanamide
• 化学式: C₁₄H₂₃N₃O₃S₂
• 分子量: 345.487
• InChiKey: QWBXJLYTPSIIML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  22
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  137
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-3-(pyridin-2-yldisulfanyl)propanamide 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors

  摘要：

  Aiming to develop selective anticancer drugs, we designed and synthesized three disulfides bearing a folic acid moiety as candidate folate receptor (FR)-targeted prodrugs of thiolate histone deacetylase inhibitors. Among them, compound 1 displayed growth-inhibitory activity toward folate receptor-positive MCF-7 breast cancer cells. The activity of I was significantly reduced by free folic acid, suggesting that cellular uptake of I is mediated by FR. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.040
• 作为产物：
  描述：

  1,8-二氨基-3,6-二氧杂辛烷 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-3-(pyridin-2-yldisulfanyl)propanamide
  参考文献：
  名称：

  Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors

  摘要：

  Aiming to develop selective anticancer drugs, we designed and synthesized three disulfides bearing a folic acid moiety as candidate folate receptor (FR)-targeted prodrugs of thiolate histone deacetylase inhibitors. Among them, compound 1 displayed growth-inhibitory activity toward folate receptor-positive MCF-7 breast cancer cells. The activity of I was significantly reduced by free folic acid, suggesting that cellular uptake of I is mediated by FR. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.040

文献信息

• [EN] SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE<br/>[FR] MIMÉTIQUES D'APÉLINE LINÉAIRE SYNTHÉTIQUE POUR LE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE
  申请人：NOVARTIS AG

  公开号：WO2014081702A2

  公开（公告）日：2014-05-30

  The invention provides a synthetic polypeptide of Formula I': or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides or bioconjugates thereof are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides or bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
• [EN] DISULFIDE CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE<br/>[FR] POLYPEPTIDES CYCLIQUE DISULFURE POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：NOVARTIS AG

  公开号：WO2015013167A1

  公开（公告）日：2015-01-29

  The invention provides a synthetic polypeptide of Formula I': X1-R-P-R-X5-X6-X7-K-X9-P-X11-X12-X13 or an amide, an ester, a salt or a bioconjugate thereof, wherein X1, X5, X6, X7, X9 and X11 to X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides or bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
• [EN] CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE<br/>[FR] POLYPEPTIDES CYCLIQUES POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：NOVARTIS AG

  公开号：WO2015013168A1

  公开（公告）日：2015-01-29

  The invention provides a cyclic polypeptide of Formula I': I or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
• [EN] CYCLIC APELIN DERIVATIVES FOR THE TREATMENT OF HEART FAILURE<br/>[FR] DÉRIVÉS CYCLIQUES DE L'APELINE POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：NOVARTIS AG

  公开号：WO2015013165A1

  公开（公告）日：2015-01-29

  The invention provides a synthetic polypeptide of Formula I': X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13 or an amide, an ester, a salt thereof, or a bioconjugate thereof, wherein X1, X3, X6, X7, X9, X11, X12 and X13 are defined herein. The polypeptides and bioconjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides and bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
• [EN] BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES<br/>[FR] BIOCONJUGUÉS DE POLYPEPTIDES D'APELINE SYNTHÉTIQUES
  申请人：NOVARTIS AG

  公开号：WO2015013169A2

  公开（公告）日：2015-01-29

  The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I': I' or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.